Geneva, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) —Entered 2026 With a Strong Commercial Momentum Expects Q1 2026 Revenue to Grow over 100% as Compared to Q1 2025 Reaffirms FY 2026 Guidance with Revenue Expected to Grow Between 50%-100% Year Over YearSEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or the “Company”), a global leader in semiconductor, PKI, and post-quantum security technologies, today announces key preliminary operational and financial metrics for fourth quarter (“Q4”) and full year (“FY”) 2025, provides first quarter 2026 revenue expectations, and reaffirms FY 2026 revenue guidance. All numbers reported are preliminary and unaudited. The Company expects to publish its audited full-year financial statements on or before March 31, 2026. FY 2025 Key Financial and Operational HighlightsFY 2025 revenue reached $18...

SMBT Jackson Summit Township BranchSouthern Michigan Bank and Trust, Jackson Summit Township BranchCOLDWATER, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) — Southern Michigan Bancorp, Inc. (OTC Pink: SOMC) announced fourth quarter 2025 net income of $2,912,000, or $0.62 per share, an increase of $262,000, or 9.9%, compared to net income of $2,650,000, or $0.57 per share, for the fourth quarter of 2024. Southern earned $12,215,000, or $2.63 per share, for the year ended December 31, 2025, an increase of $1,813,000, or 17.4%, compared to net income of $10,402,000, or $2.28 per share, for the same period of 2024. The annualized return on average assets for the years ended December 31, 2025, and December 31, 2024, was 0.77% and 0.71%, respectively. The annualized return on average equity for the years ended December 31, 2025 and...

TORONTO, Feb. 17, 2026 (GLOBE NEWSWIRE) — Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, today announced that it will release fiscal 2026 second quarter results after the close of trading on March 4, 2026. Peter Evans, Xtract One CEO and Director, and Karen Hersh, CFO and Corporate Secretary, will host a webcast and conference call at 10:00 a.m. Eastern Time the following day, March 5, 2026, to review financial results for the three months ended January 31, 2026. The webcast and presentation will be accessible on the Company’s website, and the telephone number for the conference call is 844-481-3016 (412-317-1881 for international callers). Management...

$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update. “In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to scale our impact,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech. “As we work toward our goal of launching multiple products...

Record Net Contribution of $868 million, up 10% year-over-year, including $227 million in Q4 Q4 Assets Under Administration grew by 11% year-over-year to $18.5 billionAnnounced $100 million increase to share repurchase program NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) — eToro Group Ltd. (“eToro”, or the “Company”) (NASDAQ: ETOR), the trading and investing platform, today announced financial results for the fourth quarter and full year 2025 which ended December 31, 2025. “This was a milestone year for eToro,” said Yoni Assia, CEO of eToro. “We became a publicly traded company and significantly advanced the build-out of our global financial super-app. In 2025, we accelerated product innovation and AI adoption, expanded access to global markets, broadened and localized our offering, and strengthened eToro’s footprint around the world. We...

NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide a corporate update during a live webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting...

First Quarter Fiscal 2026 Revenue of $19.5 Million,Reflecting a 10% Increase Year Over Year LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) — Daily Journal Corporation (Nasdaq: DJCO), a publishing and technology company, today announced financial results for the three months ended December 31, 2025. Total consolidated revenue for the quarter was $19.5 million, representing a 10% increase from the $17.7 million reported in the prior-year quarter, driven primarily by growth at Journal Technologies. “Journal Technologies continued to deliver solid year-over-year growth in the first quarter of fiscal 2026, driven by higher e-filing and other public service fees and recurring license and maintenance revenues,” said Steven Myhill-Jones, Chairman of the Board and Chief Executive Officer of Daily Journal Corporation. “We remain focused on...

All of the amounts disclosed in this press release are in U.S. dollars unless otherwise noted TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) — Enlight Renewable Energy (NASDAQ: ENLT, TASE: ENLT) today reported financial results for the fourth quarter of 2025 ending December 31, 2025. Registration links for the Company’s earnings English and Hebrew conference call and webcasts can be found at the end of this earnings release.The entire suite of the Company’s 4Q25 financial results can be found on our IR website at https://enlightenergy.co.il/data/financial-reports/Financial Highlights 12 months ending December 31, 2025Revenues and income of $582m, up 46% year over year Net income of $161m, up 142% year over year Adjusted EBITDA1 of $438m, up 51% year over year Cash flow from Operating activities2 of $283m, up 11% year...

Falcon Oil & Gas Ltd. (“Falcon”) Notice of Cancellation of Admission to Trading on AIM 17 February 2026 – Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) announces, in accordance with applicable AIM Rules, that the admission of Falcon’s common shares to trading on AIM will be cancelled (the “AIM Cancellation”) following completion of Falcon’s previously announced transaction (the “Transaction”) with Tamboran Resources Corporation (“Tamboran”). Pursuant to the terms of an arrangement agreement and plan of arrangement governing the Transaction, (a) Tamboran will (i) issue to Falcon 6,537,503 shares of Tamboran common stock (the “Stock Issuance”) and (ii) pay to Falcon $23,663,080 in cash and (b) Falcon shareholders (other than dissenting Falcon shareholders or Falcon shareholders subject to sanctions) will then be entitled to...

15% royalty income increase 11% total revenue increase Tripled net cash position Phase 3 program with fosmanogepix progressing as planned Financial guidance FY 2026: Double-digit increase in total revenue and operating profit Conference call and webcast today at 4 p.m. (CET)Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 17, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharma company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today its results for the financial year ended December 31, 2025. David Veitch, Chief Executive Officer, stated: “A few years ago, we set out to transform Basilea by focusing on treatments for severe bacterial and fungal infections. Since then, Basilea has become a profitable company, with consistent...